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The complete amino acid sequence of bovine colostrum cysteine proteinase inhibitor was determined by 
sequencing native inhibitor and peptides obtained by cyanogen bromide degradation, Achromobacter lysyl- 
endopeptidase digestion and partial acid hydrolysis of reduced and S-carboxymethylated protein. Achromo- 
batter peptidase digestion was successfully used to isolate two disultide-containing peptides. The inhibitor 
consists of 112 amino acids with an M, of 12 787. Two disultide bonds were established between Cys 66 
and Cys 77 and between Cys 90 and Cys 110. A high degree of homology in the sequence was found between 
the colostrum inhibitor and human y-trace, human salivary acidic protein and chicken egg-white cystatin. 
Amino acid sequence Cysteine proteinase inhibitor Bovine colostrum 
1. INTRODUCTION 
Low-M, cysteine proteinase inhibitors have been 
found in various animal tissues [l-3], sera [4-61 
and egg whites [7]. Recently, the primary structure 
of several cysteine proteinase inhibitors has been 
elucidated [8- 151. These small protein proteinase 
inhibitors are members of a family which has 
diverged from a common ancestor [14]. The in- 
hibitors identified so far are classified into two 
distinct groups, one being cellular associated 
[g-10] and the other found in extracellular fluids 
[ 1 l-l 51. Recently we purified an extracellular 
basic cysteine proteinase inhibitor from bovine co- 
lostrum [16]. Here, we report the complete amino 
acid sequence of the inhibitor and compare it with 
other low-M, cysteine proteinase inhibitors thus far 
determined. 
2. MATERIALS AND METHODS 
2.1. Materials 
Bovine colostrum was kindly supplied by Sanda 
City Agricultural Cooperative (Sanda, Hyogo, 
Japan). The silica-bonded reverse-phase columns 
for high-performance liquid chromatography 
(HPLC) were purchased from the sources in- 
dicated: YMC-Pack A 303 column (0.46 x 25 cm, 
C18, 300 A), Yamamura Chemical; LS-410 K col- 
umn (0.4 x 30 cm, C18, 100 A), Toyo-Soda; 
Baker bond wide pore butyl (0.46 x 25 cm, C4, 
330 A), J.T. Baker Chemical; ProRPC HRS/lO 
column (0.5 x 10 cm, C8, 300 A), Pharmacia. 
Achromobacter lysylendopeptidase (A. lyticus 
protease I [17]) was a kind gift from Dr T. Masaki 
of Ibaraki University, Japan. All other chemicals 
were of the purest grade commercially available. 
2.2. Isolation of inhibitors 
The isolation procedure for low-M, cysteine pro- 
teinase inhibitors from bovine colostrum was 
essentially the same as reported [16] except that 
HPLC on a reverse-phase column was used instead 
of gel filtration on a Sephadex G-50 column as the 
final step. The pooled fractions containing in- 
hibitory activity from CM-Sephadex chromatog- 
raphy were concentrated to a small volume by 
ultrafiltration on a YM-5 membrane (Amicon, 
Lexington, MA) before HPLC on a YMC-Pack 
A 303 column. The inhibitors were eluted with a 
linear gradient of 30-50% 2-propanol/acetonitrile 
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(7: 3, v/v) in 0.1% trifluoroacetic acid for 1 h at a 
flow rate of 1 ml per min. 
2.3. Peptide fragmentation and separation on 
reverse-phase HPLC 
Reduced and S-carboxymethylated (Rem) in- 
hibitor [18] was digested with Achromobacter 
lysylendopeptidase (AP) at 37°C for 6 h in 50 mM 
Tris-HCl, pH 9.5. The molar ratio of protease to 
substrate was 1:200. Digestion with the intact in- 
hibitor was carried out at pH 7.0. Methionyl bonds 
were cleaved with a lOO-fold molar excess of CNBr 
over 3 methionine residues in 70% formic acid at 
room temperature for 18 h. Partial hydrolysis was 
performed by heating Rem inhibitor with 0.03 M 
HCl (pH 2.0) in evacuated sealed tubes at 108°C 
for 2 h [19]. 
Peptides obtained by the above procedures were 
fractionated by reverse-phase HPLC using ap- 
propriate reverse-phase columns with 2-pro- 
panol/acetonitrile (7 : 3, v/v) in 0.1% trifluoro- 
acetic acid as a solvent. Columns used for peptide 
purification were an LS410K column for AP 
digests, a ProRPC HR5/10 column for CNBr 
fragments and a Baker-bond wide pore butyl col- 
umn for partial acid hydrolysate. 
2.4. Amino acid and sequence analyses 
Amino acid analyses were carried out with a 
Hitachi 83% amino acid analyzer after hydrolysis 
of samples at 110°C in vacua for 24 h in 5.7 M 
HCl or in 4 M methanesulfonic acid [20]. 
Automated Edman degradation was performed 
with a 470A protein sequencer (Applied 
Biosystems) using a standard program for sequenc- 
ing [21]. PTH-amino acids were determined by 
reverse-phase HPLC with isocratic elution as in 
WI * 
3. RESULTS AND DISCUSSION 
3.1. Isolation of cysteine proteinase inhibitors 
The result of purification using reverse-phase 
HPLC is presented in table 1. Two species of cys- 
teine proteinase inhibitor were finally purified to 
homogeneity (fig. 1). Each protein in peaks I and II 
displayed the same inhibitory activity to cathepsin 
H and gave a single band corresponding to M, 
11000 on SDS-polyacrylamide gel electrophoresis. 
The protein in peak I is always a major component 
and that in peak II minor. Only in an experiment 
shown here was a considerable amount of the in- 
hibitor isolated from peak II. Amino acid com- 
positions of both inhibitors were the same except 
that one additional residue each of glycine and 
valine was found in the protein of peak II (table 2). 
Edman degradation revealed that the inhibitor of 
the peak II had a glycine residue as amino- 
terminus which was followed by the same 23 amino 
acids found in the N-terminal portion of the major 
component of inhibitor. However, the amino acid 
sequence of the residual portion remains to be 
established. 
3.2. Determination of amino acid sequence of the 
inhibitor 
The complete amino acid sequence of the major 
component of bovine colostrum cysteine pro- 
teinase inhibitor is presented in fig.2. The strategy 
of sequencing analysis is as follows. Degradation 
Table 1 
Purification of bovine colostrum low-M, cysteine proteinase inhibitor 
Step Total 
protein 
(mg) 
Total 
inhibitory 
activity 
(units) 
Specific 
activity 
(units/mg) 
Yield 
(070) 
Purification 
(-fold) 
CM-Sephadex 0.81 1874.3 2314.0 9.2 2386 
Reverse phase HPLC 
peak I 0.15 798.6 5324.0 3.9 5489 
peak II 0.11 571.8 5343.9 2.8 5509 
Data for purification before CM-Sephadex chromatography are those presented in table 1 of [16] 
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Fig.1. Reverse-phase HPLC of crude inhibitor 
fractionated on a CM-Sephadex column. Samples 
(120rg/lOOgl) were applied to a YMC-Pack A 303 
ODS column. For experimental details, see text. 
Table 2 
Amino acid compositions of bovine colostrum low-M, 
cysteine proteinase inhibitors 
Amino acid Protein Protein 
in peak I in peak II 
(residues/mol”) 
ASP 
Thr 
Ser 
Glu 
Pro 
ClY 
Ala 
Half Cys 
Val 
Met 
Be 
Leu 
Tyr 
Phe 
LYS 
His 
Trp 
Arg 
12.8 (13)b 13.0 
3.6 ( 4) 3.7 
8.0 ( 9) 8.0 
13.5 (14) 13.8 
3.3 ( 3) 3.0 
5.4 ( 5) 6.1 
6.0 ( 6) 6.0 
3.6 ( 4) 3.8 
10.7 (14)c 11.7 
2.3 ( 3) 2.3 
1.0 ( 1) 1.1 
10.1 (10) 10.3 
2.9 ( 3) 3.0 
6.3 ( 6) 6.2 
6.1 ( 6) 6.3 
2.7 ( 2) 2.3 
0.9 ( 1) 1.0 
8.0 ( 8) 8.1 
Total (I 12) 
a Values after 24 h hydrolysis with 4 M methanesulfonic 
acid 
b Numbers in parentheses are theoretical values based on 
c 
amino acid sequence 
Discrepancy between experimental and calculated 
values may be due to the incomplete hydrolysis of 4 
Val-Val bonds in the sequence 
of the inhibitor with CNBr gave 3 peptide 
fragments (CB-I-III), which were separated by 
reverse-phase HPLC and sequenced on a gas-phase 
sequencer. Sequence information of the first 51 
residues obtained by direct sequencing of the 
native inhibitor established the arrangement of 
these 3 fragments as (CB-I)-(CB-II)-(CB-III). 
When Rem inhibitor was digested with AP, 7 
peptides (CM-AP-I-VII) were produced and 
purified completely by reverse-phase HPLC. These 
peptides were aligned based on their complete or 
partial amino acid sequences, amino acid composi- 
tions and structural information obtained from 
direct sequencing of the native inhibitor and CB- 
I-III. To overlap peptide CM-AP-V, Rem in- 
hibitor was partially hydrolyzed with dilute acid 
and peptide CM-DA was isolated. The determina- 
tion of its N-terminal 18 residues located the CM- 
AP-V in the N-terminal half of the peptide CM- 
DA. 
Two cystine-containing peptides, AP-III and 
AP-V, were detected instead of CM-AP-III and 
CM-AP-IV, and CM-AP-VI and CM-AP-VII, 
L i” 1” 18, 1” 
ALLGGLMt~UVNtLGVQ:ALSFAVSEFN~~RSNUAY~SRVV 
Fig.2 Amino acid sequence of bovine colostrum low-~, 
CYSteine Proteinase inhibitor (peak I). CB, CNBr 
fragments; AP and CM-AP, Achromobacter lysylendo- 
peptidase-digested fragments of the native protein (AP) 
and Rem protein (CM-AP); CM-DA, dilute acid hy&o- 
lysate of Rem protein. Amino acids identified by auto- 
mated Edman degradation are shown by arrows. (---+) 
Direct sequencing of the native protein, (-) 
sequencing of peptide fragment. Dashed lines denote 
identification of PTH-cysteic acid after performic acid- 
oxidation peptide. Amino acids not identified as PTH- 
amino acids are shown by thin dotted lines. Ammo acid 
compositions were determined for all the peptide 
fragments isolated. 
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Fig.3. An alignment of amino acid sequences of 7 low-M, cysteine proteinase inhibitors. (a) Bovine colostrum inhibitor 
(peak I); (b) human y-trace [13]; (c) human SAP-l [15]; (d) egg-white cystatin [11,12]; (e) rat liver TPI [8]; (f) human 
leucocytes Stefin [9] and (g) rat epidermal TPI [lo]. Boxed residues are those that are identical between other inhibitors 
and the bovine colostrum inhibitor. The alignment of Glu 26 in 3 intracellular inhibitors is tentative. AC-, acetyl-. 
respectively, on reverse-phase HPLC of the AP 
digest of native inhibitor. Direct sequencing re- 
vealed that AP-III corresponds to CM-AP-III and 
CM-AP-IV, and AP-V to CM-AP-VI and CM- 
AP-VII. After performic acid oxidation, AP-III 
and AP-V each gave 2 mol cysteic acid per mol 
peptide by amino acid analysis. PTH-cysteic acid 
was also identified by Edman degradation at the 
positions corresponding to S-carboxymethyl cys- 
teine previously determined for Rem derivatives of 
AP-III and AP-V. We conclude therefore that two 
disulfide bonds exist between Cys 66 and Cys 76 
and Cys 90 and Cys 110. 
3.3. Comparison of amino acid sequences of 
inhibitors from various sources 
Seven sequences of low-M, cysteine proteinase 
inhibitors are compared by aligning each amino 
acid with the highest homology (fig.3). Among the 
extracellular inhibitors, the colostrum inhibitor is 
highly homologous to human y-trace, a basic pro- 
tein, with 59% homology. A significant degree of 
sequence homology was also found between ex- 
tracellular and intracellular inhibitors. The co- 
lostrum protein has about 20% homology to rat 
liver protein. 
Nine amino acid residues, Leu 20, Glu 26, Lys 
29, Gln 48, Gly 52, Val59, Gly 62, Tyr 95 and Leu 
105, are conserved in the seven low-M, inhibitors 
hitherto sequenced. These residues and particular- 
ly those which are in a high homology region com- 
44 
prising residues 42-62 are likely to be involved in 
the inhibitory function of these proteins. It should 
be noted that two of the proposed reactive-site 
residues of human plasma auz-thiol protease in- 
hibitor [22] are found in the amino acids men- 
tioned above. 
Bovine colostrum inhibitor (~110.0) and human 
y-trace (pZ9.0) are basic proteins in contrast to 5 
other inhibitors. However, it is difficult to assume 
that the basicity itself plays a particular functional 
role in the inhibition of cysteine proteinase because 
of a relatively high sequence homology (45-56%) 
between acidic (~14.6-6.5) and basic extracellular 
inhibitors. 
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